March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
Investigators have identified distinct Gardnerella species with varying antibiotic resistance patterns, potentially guiding more effective treatment for recurrent bacterial vaginosis.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
Only 5% of new drug approvals included human lactation data, according to researchers calling for improved lactation pharmacokinetics research for breastfeeding women.
New research from the Mayo Clinic shows promising results for a noninvasive methylated DNA marker panel that could reduce the number of unnecessary and painful biopsies in patients with abnormal uterine bleeding.
FDA approves gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urinary tract infections in females aged 12 and older, based on phase III trial results.
The researchers found that invasive urodynamic testing did not improve outcomes or cost-effectiveness in women with refractory overactive bladder symptoms.